Abstract
Hypothalamic-Pituitary-Adrenal (HPA) axis hyperactivity measured with the dexamethasone suppression test and the dexamethesone/CRH test may have some predictive power for suicidal behavior in patients with mood disorders. Increased prolactin (PRL) levels may be related both to physiological and pathological conditions. HPA-axis abnormalities and increased levels of PRL may coexist, and common neuroendocrine changes may activate both HPA axis and PRL release. HPA-axis hyperactivity is presumably present in a large subpopulation of depressed subjects. Suicidal behavior is considered to be a form of inward-directed aggression, and aggressive behavior has been connected to high androgen levels. However, lower plasma total testosterone levels have also been reported in subjects with depression and higher suicidality. Lipid/immune dysregulations, the increased ratio of blood fatty acids, and increased PRL levels may each be associated with the increased production of pro-inflammatory cytokines, which have been reported in patients with major depression and patients engaging in suicidal behavior. Although no studies have been done to determine whether ante-mortem physical stress may be detected by raised post-mortem PRL, this would be of great interest for physicians.
Keywords: Suicidal behavior, stress, prolactin, HPA axis.
CNS & Neurological Disorders - Drug Targets
Title:Hypothalamic Pituitary Adrenal Axis and Prolactin Abnormalities in Suicidal Behavior
Volume: 12 Issue: 7
Author(s): Maurizio Pompili, Gianluca Serafini, Mario Palermo, Maria Elena Seretti, Henry Stefani, Gloria Angeletti, David Lester, Mario Amore and Paolo Girardi
Affiliation:
Keywords: Suicidal behavior, stress, prolactin, HPA axis.
Abstract: Hypothalamic-Pituitary-Adrenal (HPA) axis hyperactivity measured with the dexamethasone suppression test and the dexamethesone/CRH test may have some predictive power for suicidal behavior in patients with mood disorders. Increased prolactin (PRL) levels may be related both to physiological and pathological conditions. HPA-axis abnormalities and increased levels of PRL may coexist, and common neuroendocrine changes may activate both HPA axis and PRL release. HPA-axis hyperactivity is presumably present in a large subpopulation of depressed subjects. Suicidal behavior is considered to be a form of inward-directed aggression, and aggressive behavior has been connected to high androgen levels. However, lower plasma total testosterone levels have also been reported in subjects with depression and higher suicidality. Lipid/immune dysregulations, the increased ratio of blood fatty acids, and increased PRL levels may each be associated with the increased production of pro-inflammatory cytokines, which have been reported in patients with major depression and patients engaging in suicidal behavior. Although no studies have been done to determine whether ante-mortem physical stress may be detected by raised post-mortem PRL, this would be of great interest for physicians.
Export Options
About this article
Cite this article as:
Pompili Maurizio, Serafini Gianluca, Palermo Mario, Seretti Elena Maria, Stefani Henry, Angeletti Gloria, Lester David, Amore Mario and Girardi Paolo, Hypothalamic Pituitary Adrenal Axis and Prolactin Abnormalities in Suicidal Behavior, CNS & Neurological Disorders - Drug Targets 2013; 12 (7) . https://dx.doi.org/10.2174/18715273113129990098
DOI https://dx.doi.org/10.2174/18715273113129990098 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Part II: Targeted Particles for Imaging of Anticancer Immune Responses
Current Drug Delivery Retroviral Restriction Factors TRIM5α: Therapeutic Strategy to Inhibit HIV-1 Replication
Current Medicinal Chemistry The IL-7/IL-7 Receptor Axis: Understanding its Central Role in T-Cell Homeostasis and the Challenges Facing its Utilization as a Novel Therapy
Current Drug Targets Old and New Gasotransmitters in the Cardiovascular System: Focus on the Role of Nitric Oxide and Hydrogen Sulfide in Endothelial Cells and Cardiomyocytes
Current Pharmaceutical Biotechnology Mouse Models of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Current Pharmaceutical Design Identification of Human Acetylcholinesterase Inhibitors from the Constituents of EGb761 by Modeling Docking and Molecular Dynamics Simulations
Combinatorial Chemistry & High Throughput Screening Dietary N-3 Fatty Acids and Calorie Restriction in Autoimmune Disease:Influence in Different Immune Compartments
Current Organic Chemistry miR-126 as a Therapeutic Agent for Diabetes Mellitus
Current Pharmaceutical Design Analytical Techniques for Determining Pharmaceutical Residues in Drinking Water – State of Art and Future Prospects
Current Analytical Chemistry Possible Role of NUCB2/nesfatin-1 in Adipogenesis
Current Pharmaceutical Design Oral HPV Infection: Current Strategies for Prevention and Therapy
Current Pharmaceutical Design Organ-Level Tissue Engineering Using Bioreactor Systems and Stem Cells: Implications for Transplant Surgery
Current Stem Cell Research & Therapy Biologic Drugs in Crohn's Disease and Ulcerative Colitis: Safety Profile
Current Drug Safety Cholinergic Receptors as Target for Cancer Therapy in a Systems Medicine Perspective
Current Molecular Medicine Advances in the Development of Inactivated Virus Vaccines
Recent Patents on Anti-Infective Drug Discovery Telocytes in Liver
Current Stem Cell Research & Therapy Angiogenesis New Targets for the Development of Anticancer Chemotherapies
Current Pharmaceutical Design Subject Index to Volume 1
Current Neurovascular Research Enhancing Topical Analgesic Administration: Review and Prospect for Transdermal and Transbuccal Drug Delivery Systems
Current Pharmaceutical Design The Role of MicroRNA in Pathogenesis and as Markers of HCV Chronic Infection
Current Drug Targets